The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...

Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence. Our NLP ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

At 36 months, the disease-free survival and molecular residual disease event-free rate was 86 vs 36% for patients in the osimertinib and placebo groups. HealthDay News — For patients with resected ...

Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment of recurrent lung cancer, according to new research ...

Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study published in the ...

PTNB before surgery in stage 1 NSCLC patients is linked to higher local-regional recurrence and mortality rates. The study included 2026 patients, with 38.6% undergoing PTNB, showing higher recurrence ...

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

(CAMBRIDGE, MASS.) December 05, 2024 – Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer ...

Doctors at the University of Cincinnati Cancer Center are exploring whether personalized mRNA vaccines are effective at reducing lung cancer recurrence.The vaccines are developed from a patient's own ...